Display options
Cite
Han L, Guo X, Bian H, et al. Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway. Evid Based Complement Alternat Med. 2016;2016:4651949doi: 10.1155/2016/4651949.
Han, L., Guo, X., Bian, H., Yang, L., Chen, Z., Zang, W., & Yang, J. (2016). Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway. Evidence-based complementary and alternative medicine : eCAM, 20164651949. https://doi.org/10.1155/2016/4651949
Han, Li, et al. "Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway." Evidence-based complementary and alternative medicine : eCAM vol. 2016 (2016): 4651949. doi: https://doi.org/10.1155/2016/4651949
Han L, Guo X, Bian H, Yang L, Chen Z, Zang W, Yang J. Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway. Evid Based Complement Alternat Med. 2016;2016:4651949. doi: 10.1155/2016/4651949. Epub 2016 May 18. PMID: 27293459; PMCID: PMC4887624.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2016;2016:4651949. doi: 10.1155/2016/4651949. Epub 2016 May 18.

Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway.

Evidence-based complementary and alternative medicine : eCAM

Li Han, Xiaojuan Guo, Hua Bian, Lei Yang, Zhong Chen, Wenhua Zang, Jingke Yang

Affiliations

  1. Zhang Zhongjing College of Chinese Medicine, Nanyang Institute of Technology, 80 Changjiang Road, Nanyang 473004, China.
  2. College of Pharmaceutical Science, Soochow University, 199 Ren-ai Road, Suzhou 215123, China.
  3. Affiliated Cancer Hospital, Zhengzhou University, Dongming Road 127, Zhengzhou 450008, China.

PMID: 27293459 PMCID: PMC4887624 DOI: 10.1155/2016/4651949

Abstract

The aim of the study was to explore the possible mechanisms that Guizhi Fuling Wan (GFW) enhances the sensitivity of the SKOV3/DDP ovarian cancer cells and the resistant xenograft tumours to cisplatin. Rat medicated sera containing GFW were prepared by administering GFW to rats, and the primary bioactive constituents of the sera were gallic acid, paeonol, and paeoniflorin analysed by HPLC/QqQ MS. Cell counting kit-8 analysis was shown that coincubation of the sera with cisplatin/paclitaxel enhanced significantly the cytotoxic effect of cisplatin or paclitaxel in SKOV3/DDP cells. The presence of the rat medicated sera containing GFW resulted in an increase in rhodamine 123 accumulation by flow cytometric assays and a decrease in the protein levels of P-gp, phosphorylation of AKT at Ser473, and mTOR in a dose-dependent manner in SKOV3/DDP cells by western blot analysis, but the sera had no effect on the protein levels of PI3K p110α and total AKT. The low dose of GFW enhanced the anticancer efficacy of cisplatin and paclitaxel treatment in resistant SKOV3/DDP xenograft tumours. GFW could sensitize cisplatin-resistant SKOV3/DDP cells by inhibiting the protein level and function of P-gp, which may be medicated through inactivation of the PI3K/AKT/mTOR pathway.

References

  1. Biomed Res Int. 2013;2013:241763 - PubMed
  2. PLoS One. 2012;7(2):e32081 - PubMed
  3. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Sep 15;1001:49-57 - PubMed
  4. Cases J. 2009 Sep 01;2:6312 - PubMed
  5. Lancet. 2009 Oct 17;374(9698):1371-82 - PubMed
  6. Cell Biochem Biophys. 2015 Mar;71(2):963-9 - PubMed
  7. Chin J Integr Med. 2014 Jun;20(6):403-8 - PubMed
  8. Br J Cancer. 2010 Jul 13;103(2):178-85 - PubMed
  9. Fitoterapia. 2015 Jun;103:149-54 - PubMed
  10. Drug Metab Dispos. 2014 Apr;42(4):623-31 - PubMed
  11. Breast. 2015 Oct;24(5):548-55 - PubMed
  12. Cancer Chemother Pharmacol. 2013 Apr;71(4):829-42 - PubMed
  13. Climacteric. 2014 Aug;17(4):410-6 - PubMed
  14. Biochemistry. 2000 Dec 19;39(50):15344-52 - PubMed
  15. Curr Cancer Drug Targets. 2013 Mar;13(3):326-46 - PubMed
  16. CA Cancer J Clin. 2011 May-Jun;61(3):183-203 - PubMed
  17. Ann Oncol. 2011 Dec;22 Suppl 8:viii5-viii15 - PubMed
  18. Cancer Biomark. 2015 ;15(3):289-97 - PubMed
  19. Cancer Res. 1981 May;41(5):1967-72 - PubMed
  20. Chin J Cancer. 2010 Feb;29(2):234-8 - PubMed
  21. BMC Complement Altern Med. 2013 Sep 27;13:239 - PubMed
  22. PLoS One. 2015 Jun 22;10(6):e0127841 - PubMed
  23. Phytomedicine. 2014 Jun 15;21(7):984-91 - PubMed
  24. PLoS One. 2012;7(7):e40717 - PubMed
  25. Leukemia. 2007 Mar;21(3):427-38 - PubMed
  26. Biol Pharm Bull. 2015;38(3):425-34 - PubMed
  27. J Pharm Sci. 2016 Feb;105(2):891-6 - PubMed
  28. Oncotarget. 2015 Sep 22;6(28):25281-94 - PubMed
  29. J Biomed Biotechnol. 2011;2011:281651 - PubMed
  30. Evid Based Complement Alternat Med. 2015;2015:825805 - PubMed
  31. J Ethnopharmacol. 2005 Aug 22;100(1-2):72-9 - PubMed
  32. J Cancer Res Clin Oncol. 2013 Aug;139(8):1257-77 - PubMed
  33. Cancer Chemother Pharmacol. 2012 Sep;70(3):365-72 - PubMed
  34. J Pharm Biomed Anal. 2009 Feb 20;49(2):267-75 - PubMed
  35. Fitoterapia. 2012 Jan;83(1):117-24 - PubMed
  36. Chem Biol Interact. 2010 Aug 5;186(3):287-94 - PubMed
  37. Mol Med Rep. 2012 Feb;5(2):351-6 - PubMed
  38. Leuk Res. 2004 Jun;28(6):619-22 - PubMed
  39. Evid Based Complement Alternat Med. 2012;2012:656150 - PubMed
  40. Evid Based Complement Alternat Med. 2012;2012:359282 - PubMed
  41. Phytomedicine. 2013 Dec 15;21(1):47-61 - PubMed
  42. Biomed Res Int. 2014;2014:164391 - PubMed

Publication Types